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ABSTRACT 
The term tumor refers to an abnormal and pathological tissue characterized by a massive cell 
growth; it comprises various populations of transformed and malignant cells. These cells 
cross-communicate with each other and with different types of cells in the surrounding 
microenvironment. The nature of communication and interactions within the tumor 
microenvironment (TME) directs the fate of transformed cells via inducing pro- or anti- 
tumorigenic signals. Consequently, these cells will either succeed or fail to progress into a 
malignant growth phenotype. In the TME, fibroblasts are considered as one of the major 
cellular compartments and the primary source of non-cellular elements, including the 
extracellular matrix (ECM) and soluble factors. It has been shown that tumor cells can recruit 
fibroblasts to induce growth-stimulatory signals. On the other hand, normal fibroblasts may 
also act as tumor growth repressors. However, these actions have not been thoroughly 
addressed. The results of this thesis demonstrate the dual functionality of fibroblasts in the 
TME. First, we examined the phenomenon, whereby the normal fibroblasts inhibit tumor 
growth and development. We found that fibroblasts reduced tumor cell proliferation and 
motility through two sets of signals, the first set involved transmembrane proteins and the 
ECM. The second set was only effective after induction of the first signal, and included 
soluble factors secreted upon direct contact of the fibroblasts and tumor cells. Next, we 
uncovered the signaling pathways that were involved in the process of tumor growth 
inhibition and fibroblasts activation. We revealed a switch in fibroblasts from tumor 
suppressive cells to ones characterized by tumor stimulatory functions. Genetic ablation of 
the RhoA gene in fibroblasts significantly reduced tumor cell proliferation and motility in 
vitro, and induced tumor cell clustering in 3D-collagen matrix. Loosing of the suppressive 
function was accompanied by gaining a tumor inducing ability, since RhoA deficient 
fibroblasts enhanced tumor initiation and development by a small number of PC3 prostate 
cancer cells injected subcutaneously into immunodeficient mice. In addition, knocking out 
the RhoA gene altered the cytoskeletal organization and reduced αSMA expression in 
fibroblasts. These changes conferred the cells stiffer but less contractile compared to control 
cells. Furthermore, upon the crosstalk with tumor cells, the RhoA deficient fibroblasts 
overexpressed several pro-inflammatory genes encoding for IL6, IL8, CXCL1, CXCL5, and 
CCL5. Such a biochemical and mechanical shift in the fibroblasts reflected their pro-
tumorigenic phenotype. Using patient-derived cancer-associated fibroblasts (CAFs). We 
demonstrated that CAFs rescued tumor cells from apoptosis and could even enhance their 
growth under cis-platinum treatment. Beside the molecular mechanistic results, this thesis 
introduces a comprehensive quantitative live-cell imaging tool to investigate tumor cell-
fibroblast interactions dynamically, providing the opportunity to measure and observe cellular 
proliferation, motility, and phenotypic plasticity simultaneously. Taken together, the current 
thesis uncovers two opposite effects of fibroblasts on tumor growth. These results emphasize 
the demand for targeting both CAFs and tumor cells to treat and cure cancer patients and may 
open novel avenues for cancer prevention approaches. 
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1 INTRODUCTION 
1.1 CANCER 
Cancer is a worldwide deadly disorder. The term cancer does not refer to a single disease but 
rather to a large group of malignancies, the majority of which originate from epithelial cells. 
The cancer incidence varies according to gender, age, geographical distribution, type of 
cancer, and the level of risk factors[1-3]. Beside genetic susceptibility, the known cancer risk 
factors such as smoking [4], certain food products [5], alcohol consumption, obesity, low 
physical activity [6, 7], chemicals, and UV radiation [8] are attributed to the environment. 
Additionally, chronic inflammations and infectious agents, e.g. Hepatitis B and C viruses [9], 
Human papilloma virus (HPV), Epstein-Barr virus (EBV) [10], Human T-lymphotropic virus 
type 1 (HTLV-1), parasitic (e.g. the malaria parasite) and bacterial infections (including 
Helicobacter pylori) [11, 12], as well as the tissue specific cell division frequency of 
noncancerous stem cells [13] have been considered as risk factors for cancer. According to 
the World Health Organization (WHO), more than 8.5 million deaths were due to cancer in 
2015. Therefore, malignancies altogether are considered, as one of the most common causes 
of mortality and morbidity, and the death frequency is higher in low-income compared with 
high-income countries [14]. The human cancers are heterogeneous, but share several 
hallmarks features denoting the cellular-physiology’s alterations, including sustaining 
proliferative signaling, evading growth suppressors, avoiding immune destruction, enabling 
replicative immortality, tumor-promoting inflammation, activating invasion and metastasis, 
inducing angiogenesis, genomic instability and mutation, resisting cell death, and 
deregulating cellular energetics [15].  
Altogether, these evidences and observations motivate scientists to study cancer and to 
explore the fundamental cellular and molecular mechanisms that regulate cancer growth, 
invasion and the response to treatment.   
1.2 THE BIOLOGY OF EPITHELIAL CANCERS 
1.2.1 Epithelium 
Normal epithelial tissues are composed of polyhedral cells that bind to each other through 
different cell junctions and active adhesion molecules. They rest on a layer of connective 
tissues, where an intermediate layer of extracellular matrix (ECM) separates them. The ECM 
layer is called basement membrane, and is composed of a variety of proteins such as, the 
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network-forming collagen IV, laminin, nidogen, and proteoglycans. It usually appears as a 
thick structure under the light microscope. The basement membrane interacts with interstitial 
matrix of stromal connective tissue. Epithelial cells (EP) cover and line the surfaces and 
cavities of the body. Ordinarily, they are labile and get renewed as they undergo mitosis, 
which is a form of cell division. To divide, EP cells require entering the cell cycle, a process 
that consists of four main phases (G1, S phase, G2, and mitosis, M). The cell undergoes 
various processes, including DNA replication, cytoskeletal modification, and enzymatic 
activation during these different phases. Additionally, different circuits or switches control 
the process of the cell cycle, and thus maintaining the balance and tissue homeostasis [16, 
17]. When an error occurs during the cell cycle, several repair mechanisms are available to 
solve the problem. One of the main players in stopping the cell cycle for repair is the p53 
tumor suppressor, the guardian of the genome [18]. However, as the cell becomes incapable 
of repairing such defect, a number of intracellular surveillance mechanisms get activated to 
stop the cell from proceeding further in the cell cycle. Eventually, several multistep programs 
or signals will be triggered and transduced inside the cell, and these signaling cascades drive 
the cell into growth arrest or a programmed cell death (apoptosis) [19].  
1.2.2 Cancer initiation 
When a normal cell loses the control of the proliferation machinery and tolerates the 
intracellular surveillance mechanisms, it continuously divides, leading to an unordinary cell 
growth. Such defect in the cellular system is defined as cell transformation, upon which the 
cell becomes unable to perform normal physiological functions, and instead acquire new 
genotypic and phenotypic features [20]. The transformation of a normal cell requires genetic 
and epigenetic alterations, which activate oncogenes and/or inhibit tumor suppressor genes, 
respectively [21, 22]. Under normal condition, oncogenes (e.g. MYC and RAS), occur as 
proto-oncogenes, which play important roles in the regulation of cell growth. However, upon 
activation by means of mutation (gain-of-function), gene amplification, chromosome 
translocation or epigenetic stimulation, they turn into oncogenes and act as positive regulators 
of cell growth, which, drive the cell cycle without the requirement of external signals. 
Different sets of oncogenes are activated in different cancer types, but all cancers harbor 
oncogenes. The tumor suppressor genes (e.g. RB and p53), negatively control cell growth, 
therefore they need to be functionally inactivated in cancer cells. During normal 
physiological conditions the tumor suppressor genes are involved in the regulation of cell 
cycle, in DNA repair mechanisms and in induction of apoptosis. The inhibitions of tumor 
suppressor genes commonly occur by means of mutations (loss-of-function) including 
  
	 Introduction	 		 	
3  Twana Alkasalias    
deletions and epigenetic silencing [23-26]. Mutations are dominant in oncogenes and 
recessive in tumor suppressor genes. Thus, activation of only one copy of an oncogene can 
be sufficient for a tumor to develop, whereas both copies of a tumor suppressor gene needs 
to be inactivated [27].  
Recently, systems biology approaches have provided tools to cluster cancers according to 
their tumor suppressor or oncogenic mutational status. However, different cancer types 
show different genetic and transcriptional signatures; These variations extend over the 
patients of the same cancer type, as well as over the cell populations in the same cancer 
patient [28]. The transcriptional alteration can be driven by epigenetic changes, which 
together with the genetic changes drive tumor initiation process. It is not known which 
factors determine the cell that exhibits the genetic and epigenetic instability to initiate a 
tumor. However, it has been proposed that such cells may exhibit stem cell-like properties 
and are one of the main players in stopping the cell cycle for repair is the p53 tumor 
suppressor, the guardian of the genome thus called cancer stem cells (CSC) [29]. Also, 
tumor initiation can be driven via a dedifferentiation process, where the cells lose their 
specialized features upon epigenetic modifications and regain the progenitor cell functions 
[30].  
1.2.3 Cancer progression 
When cell growth remains localized and non-invasive, the tumor is called benign, and rarely 
causes major medical problems. In contrast, when the transformed cells start to expand and 
penetrate the neighboring normal environment, they induce malignancies [3]. For 
transformed cells to maintain their malignant phenotype, they require to sustain their 
proliferation capacity and eventually become “immortal. One of the key molecules that drive 
immortalization is the telomere, which indirectly represents the fuel for cell division via 
protecting the cell from different cell death mechanisms [31]. Therefore, the cancer cells need 
to maintain telomere length, which mainly occurs via induced telomerase activity [32]. 
Furthermore, it is necessary for the transformed cells to acquire further genomic and 
epigenetic changes in order to maintain their malignant phenotype and thus accumulate 
multiple mutations. The process needs more than four successive genetic and epigenetic 
alterations in the main cell regulatory circuits; such as the cell cycle, cell death, and 
phenotypic plasticity [33]. It is difficult to determine the exact number of steps required for 
cancer development and progression; the main limitation factors for such determination are 
tumor heterogeneity, time of diagnosis and the availability of early prognostic markers. The 
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process of cancer progression is a rather a long process, and hence correlates with aging [34]. 
However, this is not true for childhood cancer, which mostly arise due to hereditary 
malfunctions or early genetic mutations during development [35]. 
In this stage of tumorigenesis (tumor progression), the cancer cells tolerate the intra- and 
inter- surveillance mechanisms, as well as enhance the communication with the surrounding 
environment in order to invade and metastasize [36]. 
1.2.4 Cancer invasion and metastasis 
The key step in early invasion processes involves the penetration of cancer cells through the 
basement membrane. The invasive cells gradually remodel the extra-cellular matrix (ECM) 
and pave the path to facilitate the traveling away from the primary site. During this stage, the 
malignant cells start to socialize, educate the neighboring cells, and tolerate different cellular 
surveillance mechanisms. The early invasion, also called microinvasion, usually takes place 
quietly without leaving any sign behind, thus the host rarely exhibits distinct symptoms. 
Eventually, the invasive cells succeed in recruiting surrounding stromal cells, which provide 
important support for invasion [37, 38]. Furthermore, the interactions between cancer and 
stromal cells boost the invasive property of cancer cells, helping them to intravasate into the 
blood and/or lymphatic vessels [39]. In few types of cancer such as ovarian cancer, an 
alternative model of invasion has been described, where tumor cells exfoliate from the 
primary lesions, float in the ascites and directly reach the peritoneum (first site of metastasis) 
[40]. Later on, the invasive cancer cells extravasate and establish a new growth on the target 
organ, this phenomenon called metastasis. Moreover, not all invasive cells manage to initiate 
a metastatic growth on distant tissues and organs. Interestingly, specific cancer types prefer 
particular organs to colonize and metastasize. The reason behind such preferential behavior is 
not well understood [41, 42]. However, the invasive cells encounter new interactions and rely 
on the recruitment of supportive cancer associated cells at the metastatic site. At the same 
time, the cancer cells require to tolerate the anti-tumorigenic effect initiated by different type 
of cells at the pre-metastatic niche. Such action by cancer cells to prime the target site may 
start before the extravasation step.  
Taken together, the resistance to normal microenvironment and the recruitment of cancer 
associated cells, suggest the possible explanations for a particular niche selection by a given 
cancer type [43].  
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1.3 MICROENVIRONMENTAL CONTROL OF TUMOR GROWTH 
1.3.1 Overview of tumor microenvironment 
The cancer cells with its whole surrounding stromal component are called the tumor 
microenvironment (TME), which plays an important role during the process of 
tumorigenesis. It has been clearly shown that tumor development, starting from growth 
initiation, progression, invasion, and metastasis, is strongly regulated by the surrounding 
stroma or microenvironment. Therefore, within the last two decades, scientists have shifted 
their research interest also to the TME in addition to cancer cells themselves. By addressing 
the biological significance of tumor stroma and its interactions with cancer cells, it has been 
possible to demonstrate the relevance of such interactions both biologically as well as 
clinically.  
 
Figure 1. Illustration of the tumor microenvironment. Cancer cells with all different types of cellular and 
non-cellular stromal compartments. (CAF) cancer associated fibroblast, (TAM) tumor associated macrophage, 
(ECM) extracellular matrix, (PC) pericytes, (EC) endothelial cell, (T reg) regulatory T lymphocyte, (MDSC) 
myeloid derived suppressor cells, (DC) dendritic cells, (AC) adipocyte, (CC) cancer cells. 
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The structure of the TME differs according to the type, stage, and location of cancer. The 
TME can be composed of fibroblasts, endothelial cells, pericytes, macrophages, 
lymphocytes, and other immune cells as cellular compartments, and ECM as non-cellular 
compartment (Fig. 1). All these cells interact with cancer cells in multiple ways; the nature 
of these interactions is dynamic and context dependent. The outcome of tumor-stroma 
crosstalk is either issuing alliances to help cancer cell invasion, metastasis and resistance 
against treatment or the negotiation will have a negative impact on cancer cell growth, if 
the TME will initiate anti-tumorigenic responses [44-46].   
1.3.2 Anti-tumorigenic TME 
Immune surveillance  
The diversity of cellular and non-cellular TME components applies different surveillance 
mechanisms against cancer development and progression. In the early days, all of these 
mechanisms were believed to be driven via immune cells [47]. Generalization of the concept 
might be far from reality. Simply cell transformation and malignancy engages through loss of 
function rather than gaining a new one. The cancer cells are able to acquire phenotypic 
plasticity. Therefore, it is not easy for immune cells to recognize the cancer cells as nonself 
targets [48]. However, the immunocompromised people show higher cancer incidence, and 
most of these cases, such as EBV-induced immunoblastoma and papilloma related skin and 
cervical cancers are triggered virally [49].  
On the other hand, the contribution of innate immune cells in the process of surveillance is 
evident. Such cells do not require any antigenic specificity to stimulate their action. Few cells 
are involved in this phenomenon including macrophages, natural killer cells (NK), and innate 
lymphoid cells (ILC). [50]. It has been shown that, CD169+ve macrophages, localized in the 
lymph node, act as tumor antigen presenting cells activating CD8+ve antitumor T 
lymphocytes [51]. Moreover, several studies indicate that, both tumor promoting and 
suppressing macrophages (can) co-exist in the TME [52]. Gillgrass et al. have further showed 
that IL15 stimulated NK cells are tumor destructive and decrease metastatic lesions of breast 
cancer in mice [53]. Nevertheless, tumor cells have the ability to modulate and/or inhibit the 
effect of innate-immune response, thus escaping their killing activity [54, 55]. These findings 
suggest that immune cell surveillance plays a minor role in the context of host mechanisms to 
resist tumor [48].   
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Non-immune surveillance 
Humans are considered one of the most cancer resistant organisms, despite the high 
mutational susceptibility.  It’s evidenced by the fact that only about one-third of individuals 
develop tumors. On the other hand, immune cells are inefficient in recognizing and inhibiting 
cancer cell growth. Altogether, suggests the presence of immune-independent resistance 
against tumor growth and development, called intercellular surveillance. [56]. Along these 
lines, Michael Stoker and his colleagues reported one of the earliest investigations on contact 
dependent interactions between malignant and normal cells. They found that upon contact, 
the normal cells inhibit the growth of polyoma transformed cancer cells; such phenomenon 
was called neighbor suppression [57]. Similarly, normal cells have been shown to inhibit the 
growth of X-irradiated and chemically transformed cells [58]. Interestingly, injecting mouse 
teratocarcinoma cells into albino mice blastocyte developed fully normal mice, however, their 
normal organs contained small colonies that persisted during the entire lifespan [59, 60]. 
Mina Bissell’s laboratory reintroduced the concept of Rous sarcoma virus (RSV)-inducing 
tumors in the chicken [61]. They found that the destruction of the normal tissue architecture 
upon wound injury, was necessary for tumor development in normal virus-carrying chicken. 
At the site of damage, the normal cells, due to the healing process lost their inhibitory effect 
on tumor growth and development. The inhibition of malignancy by normal cells was also 
recorded upon mixing cancer cells with normal keratinocyte. This effect was maintained 
through involucrin induced terminal differentiation in transformed cells [62]. Moreover, the 
detection of the same mutation in the tumor cells and the adjacent normal cells was observed, 
suggesting that the malignant cells can be enforced in the perspective of phenotypic 
normalization [63].  
The intercellular surveillance phenomenon reflects the concept of “phenotype dominates the 
genotype”. The finding of Partanen et al. highlights the relevance of such a concept, where 
maintaining cell polarity restricts MYC-driven cellular transformation, whereas depletion of 
polarity genes induces the oncogenic effect [64]. On the other hand, the observations of 
tumor foci found relatively frequent in cancer-free individuals, suggests that intercellular 
surveillance mechanisms control tumor initiation and progression [65]. Such phenomenon is 
defined as tumor dormancy, it has been shown that dormant cancer cells can be roused upon 
chronic inflammation [66]. Recurrence of cancer after ten years from detection of primary 
tumor [67], is an example for awakening dormant cancer cells at the metastatic site. The 
chronic inflammation scenario supports the finding of wounding-stimulates RSV-inducing 
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tumor in chicken [61]. The destruction of microenvironmental architecture can be the key 
switch for tumor initiation and relapse. These changes will disturb the communication 
between cancer and normal stromal cells, as well as will disorganize the ECM, allowing the 
growth and migration of transformed cells [68]. Extracellular matrix, adhesion proteins and 
cell junctions have been considered as important players to maintain the integrity and tissue 
architecture. In a three-dimensional microenvironment/experimental setup, human breast 
cancer cells can re-gain a normal phenotype when cultured with laminin-rich gels [69]. 
Additionally, reestablishment of E-cadherin (the main structural component of adherence 
junctions) in cancer cells plays an important role in reverting the transformed cells phenotype 
[70, 71]. Another example for involvement of ECM and surface molecules in the growth 
control is β-integrins, which have different sub-types that play an important role in 
tumorigenesis. In prostate cancer, when the TME architecture is maintained; for instance, 
upon integrin-laminin polarization, a more differentiated phenotype was sustained. In 
contrast, breaking down the polarized alignment between laminin and integrins, promotes the 
malignant phenotype [72]. Interestingly, in naked mole rats, a cancer resistant rodent model, 
the presence of extraordinary-high molecular weight hyaluronan protects the animal from 
developing cancer. The only way to induce cellular transformation in vitro, is either through 
knocking down the enzyme hyaluronan synthase 2 (HAS2) or knocking-in the degradation 
enzyme [73]. 
The above-mentioned observations support the significance of intercellular surveillance in 
tumorigenesis. Apart from the TME, there are other surveillance systems clustered under the 
category of “inter-cellular surveillance”, which have not been highlighted in the present 
thesis. For a better understanding of tumor resistant behavior of the TME, it is of high 
demand to perform more comprehensive studies and address such phenomenon 
systematically.  
1.3.3 Pro-tumorigenic effect  
Malignancies arise when transformed cells pass the border of inter- and intra- cellular 
surveillances. Eventually, the structure and functions of the TME will change; instate of 
initial anti-tumorigenic activity, the TME becomes/switches to protective and supportive 
for tumor cells [74]. The gaining of supportive function occurs gradually and concurrently 
with the loss of the inhibitory one. Furthermore, the disturbance of stromal architecture 
results in accumulation of tissue damage, which in turn initiates different signaling cascades 
that induce cancer cell proliferation, progression, and invasion [75]. In addition to the 
inflammation, another examples for accumulation of damage is aging; the 
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microenvironment undergoes massive changes with age, and correlation between cancer 
incidence and elderly is well documented [76].  
As mentioned, the signatures for early stage carcinogenesis, involves enriched genetic 
instability and stimulation of proliferation machinery. Subsequently the epithelial cells 
undergo several morphological changes (atypia), and the abnormal cells produce a small 
outgrowth called carcinoma in situ (CIS)[77]. Such growth will not develop to malignant 
tumor unless it gets support from the surrounding niche. As transformed cells transduce 
signals and interact with the stroma through the ECM and surface molecules, they start to 
grow expansively [78]. Losing of basement membrane integrity is fundamental for 
achieving such communication. For example, vanishing of Laminin 1, a component of 
plasma membrane and a key provider of polarity, allowed integrin-mediated direct contact 
between the transformed cells and interstitial ECM [79]. This contact will induce the tumor 
cells to secret different factors including matrix metalloproteinases (MMPs), which 
modulate the ECM and help tumor cells to invade [80]. Tumor cell-ECM interactions 
induce different signaling cascades in tumor cells, which can be conducted to initiate two 
actions: first an autocrine effect on cancer cells that can boost their invasive activity, and 
second a paracrine effect that can enhance the recruitment of variety of cells in the TME. 
Such cells, obtain an abnormal phenotype to help tumor growth, progression, invasion and 
metastasis. These cells include fibroblasts, endothelial cells, pericytes, adipocyte, 
macrophages, and different immune modulatory cells such as, regulatory T-cells (T-regs) 
and myeloid derived suppressor cells (MDSCs) [46].  
Apart from fibroblasts, which the present thesis emphasizes on, the following section will 
introduce and highlight the contribution of other stromal cells in the process of 
tumorigenesis. 
Endothelial cells (EC) 
Endothelial cells are lining the blood vessels, and usually are stable genetically, but acquire 
phenotypic changes when they are associated with cancer [81]. Recruitment of ECs by 
cancer cells enhances the process of “angiogenesis”, i.e. the formation of new blood vessels 
from the existing ones. This process is highly demanded by tumor cells for two reasons, 
first; to supply cancer cells with nutrition, oxygen and growth factors, and second; to 
sustain and enhance cancer cell growth, invasion, and metastasis. The newly formed 
vasculature has an unstable and disordered structure, as compared to the corresponding 
normal vessels, and this abnormality is due to the persistently triggered signals and 
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absences of the normal regulators [82, 83]. Generally, tumor cells and other cells in the 
TME secrete VEGF, which binds to the corresponding receptor on endothelial cells, and as 
a result, induces a series of signals that break the endothelial cell-cell junctions. The holes 
between ECs will facilitate the intravasation of cancer cells and also will represent a site for 
fluid leakage, which in turn enhances the chaotic tumor configuration [84]. Recently 
Wieland et al. revealed that upon activation of the Notch 1 receptor on endothelial cells via 
corresponding ligand on cancer cells, the former undergoes different morphological and 
functional changes, which stimulates tumor cell invasion and metastasis [85]. Also, the 
crosstalk between cancer cells and endothelial cells may reduce the tumor suppression 
signaling cascades. It has been shown that, in response to the signals from cancer cells, the 
ECs downregulate the expression of Slit2, which has a tumor suppressor activity and thus 
helps in sustaining tumor cell growth [86]. 
Pericytes (PC) 
While ECs are lining the lumen of blood vessels, PCs locate on the other side of the basement 
membrane, which forms the main adhesion surface to both of these cell types [87]. The PCs 
establish a physical contact with endothelial cells and support the overall vessel’s structure, 
whereas, upon recruitment by tumor cells, the contact become loose and weak [88]. The 
recruitment of PC is associated with different signaling pathways such as TGFβ, PDGF, 
Notch and angiopoietin. Most likely the PC-tumor cell interaction is beyond the two 
dimensional relationship; this means that other stromal cells can influence the PC-tumor cell 
interaction, for e.g. ECs secret PDGF that bind to corresponding receptor in PCs and PDGF-
activating PCs support tumor cell growth and invasion [89]. Tumor associated PCs are 
characterized by expression of different markers such as α-SMA, PDGF receptor α and β, 
desmin and others [90]. According to the type and stage of cancer the PCs may show 
different responses; for example, the effect of depleting PCs in the early stages of 
carcinogenesis has been found to be negative on cancer cell growth. In contrast, when the 
depletion was maintained at advanced stages, the cancer cell growth and metastatic rate were 
induced significantly [91]. In addition, the number of PCs on vasculature can affect cancer 
cell growth and invasion, since the coverage density of PCs was proportionally related to low 
invasive property of cancer cells in a prostate cancer model [92]. 
Adipocytes   
The knowledge about adipocytes as inflammatory cells has recently been emerging. 
Previously, these cells were believed to mainly represent storages for lipid and energy [93]. 
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These cells are now known to produce different cytokines and adipokines, such as IL-1β, 
TNFα, CCl2, and IL6, changing the inflammatory properties of the TME and the recruitment 
of various immune cells [94]. However, such switch in the nature of microenvironment 
resembles the condition of chronic inflammation, which shifts the TME to be more pro-
tumorigenic [95, 96]. In a mouse model, macrophage infiltration was decreased upon obesity-
induced inflammation [97]. On the other hand, upon recruitment by tumor cells, adipocytes 
can dedifferentiate back to fibroblast like cell, releasing free fatty acids, which can be utilized 
by cancer cells as source of energy to sustain their growth and invasive phenotype [98]. In a 
breast cancer models, the cancer associated adipocytes induce tumor cell growth and 
aggressiveness [99]. Additionally, in mice lacking the Stromelysin-3 (MMP3) gene, the 
adipocytes decreased the initial cancer cell survival and invasion into the surrounding 
connective tissue [100]. 
Immune cells 
Among the variety of immune cells in the TME, macrophages constitute an abundant sub-
type [101]. The polarization of macrophages by tumor cells occurs through a variety of 
ligands, which modulate macrophage functions. They show a wide range of plasticity in 
response to cancer growth and progression. Broadly, macrophages can be categorized into 
two sub-types; the phenotype, which shows an anti-tumorigenic effect, called type 1 
macrophages (M1), whereas type 2 macrophages (M2) represent the tumor stimulatory 
phenotype [102]. Generally, pro-inflammatory ligands such as TNFα, IFNγ, lipopoly-
saccharide and GM-CSF stimulate M1 macrophages [103, 104]. M2 macrophages get 
stimulation through TGFβ, IL10, IL4, IL13 and glucocorticoids [103, 105].  
In response to stimulation, the M1 macrophages induce the pro-inflammatory signature of the 
TME via secreting different cytokines including IL1β, IL6, and TNFα. In contrast, the M2 
subtype secretes more anti-inflammatory ligands such as IL10, TGFβ, prostaglandin E2, and 
IL1 receptor antagonist. The M2 subtype also induces the angiogenic signals and MMP 
expression by stromal cells [106]. It has been shown in ovarian cancer patients that the high 
M2 density correlates with bad prognosis [107], while the high M1/M2 ration correlate with a 
better survival [108]. Additionally, increased numbers of M2 macrophages were recorded in 
prostate cancer tissue as compared to intraepithelial neoplasm and normal prostate [109].  
In addition to TAM, there are other immune cells recruited into the TME. Myeloid derived 
suppressor cells (MDSCs) are recruited from the bone marrow into the TME. These cells 
normally suppress the immune activity [110], and the tumor associated MDSCs have been 
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reported to suppress the anti-tumor activity of immune cells in different cancers. In pancreatic 
cancer mouse model, the recruitment of MDSCs inhibits cytotoxic T cells in vitro and 
enhances tumor growth in vivo [111]. In recent study, the Hippo-YAP pathways showed to 
promote the recruitment of MDSCs, which were essential for prostate cancer growth and 
progression [112] 
 
Figure 2. Microenvironmental control of tumor growth. The TME can either act as tumor growth 
suppressor and shows anti-tumorigenic effect, or act as tumor growth stimulator and induce pro-tumorigenic 
effect. Different TME compartments are involved in driving such effects.  AC (adipocyte), T-reg (regulatory 
T cell), MDSC (myeloid derived suppressor cell), TAM-2 (tumor associated macrophage-type 2), EC 
(endothelial cell), PC (pericyte), ECM (extra cellular matrix), CAF (cancer associated fibroblasts), NF 
(normal fibroblast), DC (dendritic cell), CTL (cytotoxic T lymphocyte), NK (natural killer cell), EpC 
(epithelial cell), TAM-1 (tumor associated macrophage-type 1), CC (cancer cell). 
The regulatory T-lymphocytes (T-regs), are another example of pro-tumorigenic immune 
cells recruited into the TME. The infiltration of T-regs into the tumor has been correlated 
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with poor patient survival. However, recent observations indicate the existence of different 
sub-types of T-regs reflecting their heterogeneous and context dependent responses (in 
different cancer patients) (for review [113]). 
Collectively, the microenvironmental control can drive the process of tumorigenesis forward 
or backwards (Fig. 2). All cellular and acellular components of the TME interact with cancer 
cells and with each other to orchestrate this process.  
1.4 FIBROBLASTS  
1.4.1 Overview of the structure and origin of fibroblasts 
Fibroblasts constitute the most abundant cell types in the stroma. They produce and 
reorganize various ECM proteins, supporting the architecture of tissues and organs. Such 
organization provides tissues and organs with the appropriate environmental condition to 
perform their functions efficiently. Additionally, fibroblasts interact with the neighboring 
epithelial, endothelial and immune cells, as they secrete and respond to different signaling 
molecule including cytokines, chemokines and growth factors. Consequently, they play a 
vital role during the process of tissue development, repair, and homeostasis [114-116]. The 
current knowledge has shifted fibroblasts from being rather generic to more tissue specific 
and context dependent cells. A comprehensive study by Rinn et al. showed that human 
fibroblasts exhibit transcriptional programs according to their anatomical site of origin. A 
total of 47 primary fibroblasts, isolated from 43 different anatomical sites were included in 
the study. The mutual genetic expression pattern allowed the clustering of fibroblasts into 
three anatomical location-based categories; first, anterior and posterior, second, proximal 
versus distal, and third, dermal against non-dermal sites of the body [117]. Later the same 
research group found that these genetic variations in fibroblasts are controlled and maintained 
by epigenetic modifications [118]. Altogether, these results highlight the plastic nature of 
fibroblasts. 
Fibroblasts are quiescent cells during normal physiological conditions, whereas stress or 
injury stimulates them at the sites of tissue damage. This is the situation during inflammation, 
wound healing, and fibrosis-induced diseases. What is unclear is whether the recruited 
fibroblasts originate mainly from local quiescent fibroblasts or from other types of cells by 
transdifferentiation. As shown in Figure 3, the tissue injury or inflammation-associated 
fibroblasts can originate from at least four different cell types [114, 119]. These include local 
tissue resident fibroblasts. However, the low proliferative rate of tissue-resident fibroblasts 
challenges the model of local fibroblast activation. Fibroblasts can also arise from epithelial 
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cells through a process called epithelial-to-mesenchymal transition (EMT), which can occur 
during inflammation, cancer, rheumatic arthritis, and other pathological conditions [120]. 
During this process, the epithelial cell loses the epithelial cell junctions and polarity, 
coincident with cytoskeletal reorganization and morphological change [121]. Mesenchymal 
and endothelial progenitor cells could also be considered as the precursors for the 
accumulation of fibroblast like cells [122]. In a rabbit ischemic model, angioblasts could be 
recruited from the blood stream into the sites of vasculogenesis [123]. It has been shown that 
cells of mesenchymal phenotype are circulating in the blood; interestingly, such circulating 
cells share similar characteristics with the fibroblasts that accumulate in the joints of patients 
with rheumatic arthritis [124].   
 
Figure 3. Fibroblasts differentiation process. Upon stimulation fibroblast arises from different type of cells. 
MPC (mesenchymal progenitor cell), VPC (vasculature progenitor cell). 
Another putative source for disease-related accumulation of fibroblasts are fibrocytes, which 
constitute less than 0.5% of non-erythrocytic cells in the blood. They can induce tissue 
remodeling upon entry into the site of injury. Fibrocytes are spindle-shaped adherent cells 
and arise from a sub-type of blood circulating monocytes. They differentiate into fibroblasts 
in response to TGFβ and other cytokines [125, 126]. Since both fibroblasts and adipocytes are 
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of the same mesenchymal lineage, it has been suggested that, during carcinogenesis, the 
adipocyte represent the source of active fibroblasts [127]. Adipose tissue mesenchymal cells 
can convert to fibroblast like cells that induce the growth of human pancreatic cancer cells in 
BALB/cAJcl-nu/nu mice [128]. 
1.4.2 Functions of fibroblasts 
The most important functions of fibroblasts include the ECM production, degradation, and 
interactions. Therefore, they are considered as essential elements driving matrix homeostasis 
[129]. Similarly to the type of fibroblasts, the configuration of ECM varies according to the 
localization and type of tissue. Such diversity provides a framework for the tissue specific-
residential cells to navigate through the ECM [130, 131]. Examples for the ECM proteins 
produced by fibroblasts are collagens (e.g. type I, III and V), proteoglycans, fibrin, 
fibronectins, glycosaminoglycans, and other ECM fibrils, which configure into a three 
dimensional network and generate an osmotic-active scaffolds [129, 132, 133]. Fibroblasts 
also participate in the formation of basement membranes via synthesizing and secreting 
laminin and collagen IV [134]. Additionally, upon stimulation during injury or pathological 
conditions, the activated fibroblasts interact with ECM through different adhesion molecules 
and signaling receptors. As a result, and according to the type of interactions and stimulation, 
the fibroblasts synthesize and degrade particular ECM molecule [135]. Fibroblasts express 
different surface adhesive molecules such as integrins, sydecans and cadherins, which 
represent the mediators for fibroblasts-ECM interactions. Such cell-ECM interaction engages 
a range of signaling cascades, which influence cellular proliferation status, enhance or inhibit 
the pro- and anti-inflammatory responses, directing apoptotic versus survival signals, and 
inducing the secretion of different soluble and growth factors [136, 137].  
Fibroblasts participate in ECM remodeling via expression of different matrix-degrading 
proteases (including their inhibitors), which are enzymes essential to tissue maintenance and 
repair. Several families of these enzymes are known, including MMPs, cathepsins, urokinase-
plasminogen system proteins tissue inhibitors of metalloproteinases (TIMPs), and 
aggrecanases [138, 139]. Generally, fibroblasts produce different types of MMPs upon 
stimulation via various pro-inflammatory cytokines and growth factors, such as IL1α and β, 
fibroblast growth factor (FGF), PDGF and others [140, 141].  
In addition to the ECM synthesis and remodeling, fibroblasts recruit immune cells to the site 
of damage by producing a wide repertoire of inflammatory mediators, or expressing Toll-like 
receptors (TLRs). Additionally, they can sensitize bacterial lipopolysaccharide (LPS) through 
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secreting range of chemokines, which in turn induce the recruitment of inflammatory cells 
[142, 143]. 
1.5 FIBROBLASTS: AN ASPECT OF NEIGHBOR SUPPRESSION 
The neighbor suppression is a phenomenon defined as the ability of particular normal cells 
to inhibit the growth of adjacent abnormal or transformed cells by direct or indirect contact. 
Such phenomenon represents a vital form of intercellular surveillance [144]. Michael 
Stoker and co-workers discovered that mouse fibroblasts, upon contact, inhibit polyoma 
virus-transformed cells in vitro [57]. Surprisingly, Kirk et al. showed that the inhibition of 
tumor cell growth by normal lung fibroblasts is contact independent, but require the 
presence of the fibroblast secretome [145]. Other studies demonstrated that the paracrine 
inhibitory effect of TGFβ, TNFα, and IL6 against tumor cells is triggered upon mixing 
tumor cells and fibroblasts in a co-culture system [146-148]. The inhibitory effect of 
fibroblasts against their transformed derivatives can be mediated through the gap junction 
intervening the communications between these two types of cells [149, 150]. However, 
conflicting results have been reported in a different study, where the inhibitory effect was 
shown to be independent of gap junction [151], but depend on the type of fibroblasts and 
transforming oncogene [151, 152]. 
On the other hand, about four decades after his first discovery, Stoker and his colleagues re-
introduced the concept of “neighbor suppression” based on results with the suppressor and 
non-suppressor mouse fibroblasts against SV40 transformed derivatives. They found that 
the inhibition was independent of gap junction or apoptosis, but it was driven through the 
cell cycle arrest in G2/M phase [153]. Furthermore, Flaberg et al. from our group, showed 
by using a high throughput proliferation assay, that mouse fibroblasts are capable of 
inhibiting both; the mouse transformed fibroblasts and human tumor cells, suggesting that 
the inhibitory effect could predominate across species [154]. The study was further 
extended to investigate the impact of 107 primary human fibroblasts isolated from pediatric 
and adult patients, obtained from different tissues including skin, mastectomy-resected 
tissue, inguinal-hernia, nasal polyps, and prostate. However, to compare the suppression 
efficiency, the ﬁbroblasts were clustered into two groups, one represented the internal organ 
fibroblasts and the other as skin ﬁbroblasts. The effect was investigated against six different 
human cancer cell lines; three from prostate, two from lung and an EBV transformed 
lymphoblastoid cells. Interestingly, fibroblasts inhibited the cancer cell proliferation, and 
the range of inhibition varied according to the fibroblastic-site of origin and donor’s age. 
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Skin and pediatric fibroblasts were more effective suppressers of tumor cell proliferation, as 
compared to the internal and adult fibroblasts [154]. Moreover, in a separate study, the 
inhibition of tumor cell proliferation and activity depended on the architecture of fibroblast 
monolayer in the co-culture. The confluency of fibroblast monolayer affected the 
proliferation score of cancer cells; the more confluent the fibroblast layer was, the more 
inhibitory the fibroblasts were [155]. Normal dermal fibroblasts have also been found to 
inhibit the onset of melanoma tumor in mouse model; fibroblasts enhanced cell cycle arrest 
in melanoma cells, which showed reduced p16 and cyclin D1 levels thus low proliferation 
rate [156].  
Several questions can be addressed about the potential relevance of neighbor suppression, 
in specific during cancer initiation and dormancy. More comprehensive studies are required 
to investigate the molecular mechanism behind this phenomenon and to identify the 
possible links between cancer inhibiting and cancer promoting phenotypes. 
1.6 QUIESCENT, ACTIVATED, AND CANCER ASSOCIATED FIBROBLASTS 
(CAF) 
Fibroblasts, at the physiological conditions, are generally localized in the interstitial stromal 
spaces between the parenchymal tissues [157]. They have a quiescent phenotype, which 
from a molecular perspective still remains incompletely characterized. However, they are 
known to be susceptible to a various stimuli, upon which their physiological status changes 
and they become activated [158]. The activated fibroblasts present inexhaustible protein 
synthetic activity and contractile functions, which are fundamental during the formation of 
new connective tissue and throughout the wound healing process [159].  
Upon activation, the shape of fibroblast changes from fusiform, bland and elongated to a 
wide-cruciform structure, also called myofibroblasts (Fig. 4). The activated cells express 
several markers that can be distinguishable in vivo and in vitro, such as αSMA, PDFGRβ, 
and fibroblast activation protein (FAP) [160]. In contrast, absolute markers for the 
identification of quiescent fibroblasts are still under debate. The one that is routinely used 
called fibroblast specific protein 1 (FSP1), also called S100A4. However, it is expressed 
also in other cells such as macrophages and few cancer cells [161, 162]. When compared to 
quiescent fibroblasts, the activated cells are more migratory and vulnerable for epigenetic 
modifications, which allow serving as precursors for different cell types. Eventually, they 
enhance their proliferation machinery, ECM production and altered secretome [163-165].  
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Figure 4. Fibroblast activation process (classical theory). Quiescent fibroblasts respond to stimuli such as 
TGFβ, PDGF, and IL1β, and thus exhibit morphological changes and express range of markers such as SMA, 
FAP, PDGFR and secret various proteins including MMPs, interleukins and growth factors. 
Recently, the notion of fibroblast activation process has been challenged, suggesting the 
existence of two activated phenotypes. The first is reversible, which is indicated during 
wound healing process; the fibroblasts are morphologically flattened and express αSMA and 
Vimentin (Fig 5). Also they acquire contractile properties, induce cytoskeletal 
rearrangements, and enhance ECM production and remodeling. Such features are 
accompanied with moderate, but adequate, secretory functions to fuel the 
microenvironment and sustain the proliferation and migration machineries. As the repair 
process is accomplished, the activated fibroblasts undergo programed cell death or 
experience epigenetic reprogramming [132, 166]. It has been shown that myofibroblasts 
exhibit a transient activated phenotype and can be de-differentiated to quiescent form in the 
presence of IL-10 [167]. 
The second sub-type of activated fibroblasts is irreversible, where the fibroblasts are 
continuously exposed to the stimuli. Such phenotype represents the CAFs, which 
accordingly obtain unique features assembled as excessive and specific secretory and ECM 
remodeling phenotypes. Also, they acquire an autocrine signaling ability and a greater 
proliferative efficiency [166, 168]. Generally, the activated fibroblasts require epigenetic 
modification in order to convert into pro-invasive CAFs. It has been shown that LIF 
(leukemia inhibitory factor) induces an epigenetic switch in the fibroblasts resulted in 
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continuous activation and obtaining cancer-associated phenotype [169]. The special 
immunomodulatory functions of CAFs is represented by massive production of cytokines 
and chemokines, including PDGF, VEGFA, PGE2, IL-6, TNF, NF-κB, IL-8, HGF, and 
CXCL12, [170-174]. Moreover, their specific ECM remodeling ability is attributed to the 
production of certain MMPs, such as MMP1, MMP2, MMP3, MMP9, MMP13, and TIMPs 
[175-178]. CAFs can be identified, both in vivo and in vitro, through a panel of markers 
such as, PDGFR α and β, αSMA, FAP, and FSP1 [179-181]. Since these proteins can be 
expressed by different cells, other than CAFs, therefore, it is recommended to use more 
than two - three of them simultaneously, along with specific epithelial or tumor markers, as 
a control, to identify them precisely. Furthermore, different studies revealed different CAF 
signatures, for example, analyzing more than 2500 proteins using the Protein Atlas database 
revealed twelve new CAF markers (ARHGAP26, ARHGAP31, AZI2, BHLHE40, DLG1, 
EGLN1, ITCH, PKM2, PLOD2, RAB31, ROCK2, and RNF19A) [182]. The signature was 
identified to represent CAFs in five different cancers (lung, colorectal, breast, basal cell and 
squamous cell carcinoma). In a colon cancer study, using quantitative proteomic analysis a 
new CAFs signature was identified, as assembled by four markers (CDH11, FSTL1, 
LTBP2, and OLFML3) [183]. Such observations indicate that CAFs are highly 
heterogeneous cell populations, revealing a definite expression patterns depending on the 
type of cancer or even within patients of the same cancer type. It has been shown that in 
different cancers, such as colon, esophageal squamous cell, non-small cell lung, and breast 
cancer, different patients (diagnosed with the same cancer type) exhibited different 
fibroblastic-gene signatures. Moreover, such variety could be used as prognostic factors 
since it clustered the patients into high and low risk groups [184-187]. 
Altogether, the two-step fibroblast activation model, differentiating the normal active 
fibroblasts from the CAFs, further supports the concept of fibroblast’s dual behavior 
against tumor cell growth and development. Investigating the exact molecular mechanisms, 
which direct the action of each phenotype, thus defining them autonomously, may 
significantly drive our knowledge toward the possible cancer treatment and prevention 
strategies. 
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Figure 5. The two-stage model of active fibroblasts. A) Normal active fibroblast (reversible activation), B) 
Cancer associated fibroblast (irreversible activation). The CAFs acquire specific and effective secretory 
properties and also exhibit unique ECM remodeling properties. 
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1.7 CANCER ASSOCIATED FIBROBLASTS: AN ASPECT OF 
CARCINOGENESIS 
1.7.1 The impact of CAFs on cancer initiation 
The switch of normal fibroblasts into CAFs is one of the most fundamental steps in tumor 
development. Due to the difficulty in defining the threshold of cancer onset, the impact of 
fibroblasts on tumor initiation process is debatable. The concept of “the egg and chicken” is 
applicable; who comes first? Transformed cell recruit fibroblast or the activated fibroblast 
induces epithelial cell transformation and malignancy? Observations, which highlight the 
merit of each strategy over the other, are available. The majority of these studies have been 
done in mice or in vitro. One of the investigations revealed that CAFs isolated from prostate 
cancer patients induced epithelial cell transformation and immortalization, as well as, shifted 
the non-tumorigenic feature of the epithelial cell line into highly tumorigenic one [188]. 
Different experimental models, such as gene modification, overexpression and deletion 
contributed to demonstrating the role of fibroblasts in tumor development processes. One of 
the studies showed that Wnt1 overexpressed fibroblasts could transform mammary epithelial 
cells isolated from C57BL/6 mice [189]. A number of observations suggested the 
contribution of TGFβ signaling in the process of cancer initiation. A study performed in mice, 
an irradiated microenvironment decreased cancer latency and boosted the development of 
aggressive mammary tumor upon p53-null epithelial cells transplantation in mice. This effect 
was mediated through TGFβ; genetically knocking down TGFβ abolished the effect on 
latency [190]. Furthermore, knocking-out TGFβ receptor II in FSP-1-positive fibroblasts 
promoted prostate intraepithelial neoplasia and fore-stomach squamous cell carcinoma [191]. 
Whereas, in FSP1 (S100A4)-null mouse model, the mice showed significantly delayed and 
decreased tumor initiation rate upon injecting highly metastatic mouse mammary carcinoma 
cells, while when the cancer cells were co-injected with fibroblasts expressing FSP1, they 
partially enhanced tumor development process [192].  
Trimboli et al. showed that PTEN inactivation in fibroblasts significantly enhanced the 
malignant transformation, initiation, and growth of mammary adenocarcinoma in mice. They 
also observed immune cells infiltration and substantial increased ECM remodeling, and 
interestingly the transcriptomic analysis of PTEN-inactivated fibroblasts showed a high 
correlation with breast CAFs in human patients [193]. An elegant study showed that 
senescence drives the fibroblasts to induce tumor growth, where osteopontin-producing 
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senescent fibroblasts enhanced the pre-neoplastic growth of epithelial cells in mice and in 
vitro; the effect of osteopontin was mediated through the activation MAPK pathway.  
Moreover, senescent fibroblasts promote tumorigenesis through expressing IL6 and recruiting 
immunosuppressive signals [194-196]. A recent study highlights the role of CAFs in 
initiating ovarian cancer growth in vivo and inducing sphere formation in vitro. This 
fibroblast function was through enhanced expression of FGF4, which binds to FGFR2 on 
tumor cells and this signaling was essential to boost the growth and proliferation of ovarian 
cancer cells [197].   
1.7.2 The impact of fibroblasts on cancer progression 
Several observations and studies highlight the important role of CAFs in the process of tumor 
growth and progression, indicating a significant impact on tumor identification and 
suggesting new treatment strategies. CAFs have been shown to induce tumor growth by 
different experimental models, such as in vitro, mouse, and human patient models. One of the 
studies indicated the promoting effect of CAFs, as compared to normal fibroblasts, in 
inducing the progression of initiated non-tumorigenic prostatic hyperplasia into a tumor 
growth. Interestingly, under identical experimental condition, the CAFs were unable to 
induce the growth of normal prostate epithelial cells [198]. This suggests that CAFs do not 
participate in tumor initiation process, while significantly promote the progression of an early 
initiated growth.  
Other studies revealed that CAFs boost tumor progression and development via specific 
secretome activity. CXCL12 (also called SDF1) secreted by CAFs enhance tumor growth via 
interacting with CXCR4 receptor on tumor cells; as a result exerting different signaling 
cascades, which enhance tumor cell proliferation and motility. This effect has been 
documented in different cancer models such as breast cancer [199], endometrium cancer 
[200], adenocarcinoma of the esophagogastric junction [201], melanoma [202, 203], and 
others. Apart from CXCL12, using a prostate cancer model, the autocrine signaling of 
CXCL14 in CAFs showed to enhance tumor growth significantly [204]. The high expression 
of CXCL14 was dependent on the activation of NOS1 in the CAFs [205]. 
 The secretion of pro-inflammatory cytokines by CAFs plays a vital role in tumor growth and 
progression [206, 207]. As shown in endometrium cancer, IL-6 secreted by CAF stimulates 
cancer cell proliferation via STAT3/c-MYC signaling pathway [208]. In a melanoma model, 
fibroblasts lacking PDEF (pigment epithelium-derived factor) could induce tumor cell 
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growth in vitro and in vivo, as the tumor stimulatory fibroblasts exhibited a high expression 
level of IL8, SERPINB2, and hyaluronan synthase-2 [209].  
 Different transcription factors have been identified in CAFs as drivers for their tumor 
stimulatory functions. Scherz-Shouval et al. showed that HSF1 (heat shock factor 1) is highly 
expressed in CAF isolated from breast and lung cancer patients. Interestingly, HSF1 could 
directly bind to CXCL12 and enhances its expression in CAFs, thus mediating tumor growth 
and progression. They also found that high HSF1 expressing CAFs was related to poor 
prognosis in lung and breast cancer patients [210]. YAP1 (Yes-associated protein 1) is another 
example of over-activated transcription factors in CAFs, which showed to increase the ECM 
stiffness thus enhancing tumor cell growth and invasion [211]. 
On the other hand, tumor growth stimulation can be mediated through ECM remodeling and 
degradation by various MMPs secreted by CAFs. MMP3, which is highly expressed by 
activated fibroblasts, can cleave E-cadherin and promote tumor progression and invasion 
[212]. Recent study indicate that MMP3 expression in CAFs is lower than prostate cancer 
cells due to inhibition of where reactive oxygen species such as hydrogen peroxide, MMP3 
expression in CAFs, but enhanced its expression in prostate cancer cells [213]. Upon tumor 
cell activation, stromal fibroblasts could also secret MMP9 [214], which is essential for breast 
cancer cell growth via its function in disrupting tissue polarity and architecture of 
microenvironment [215]. Overexpression of TIMP1 has been recorded in CAFs; such 
induction played a vital role in supporting prostate and colon cancer progression in vivo 
[216]. In contrast, knocking-out all four members of TIMP family in fibroblasts enhanced 
breast cancer cell motility and cancer stem cell-like properties. TIMP inactivation was 
sufficient for CAFs markers acquisition; CAFs in turn secreted exosomes enriched with 
MMPs and ECM proteins. The authors showed ADAM10-rich exosomes activate RhoA and 
Notch signaling in breast cancer cells, thus driving their activity and stem cell property [217]. 
Another study revealed that concomitant inactivation of Notch effector CSL and p53 
stimulate CAF and tumor cell expansion [218]. 
1.7.3 The impact of fibroblasts on cancer metastasis 
Cancer associated fibroblasts are essential intermediates of secondary tumor growth at the 
distant site, even though; their effect on cancer cells might start at the primary site. As CAFs 
secret range of cytokines, chemokines and growth factor, which in turn stimulate the cancer 
cell invasion and metastasis. IL6 secreted by CAFs could activate JAK2-STAT3 pathway in 
gastric cancer cells and boost their migration and the ability to undergo EMT. The inhibition 
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of IL6 or JAK2-STAT3 pathway in CAFs or cancer cell, respectively, reduced the metastatic 
rate to the peritoneum [219]. Another gastric cancer study showed that the high SRF 
expression (serum deprivation factor) in fibroblasts induces cancer cell metastasis via 
enhancing the CXCL12/CXCR4 signaling [220]. The CXCL12 producing fibroblasts can 
enhance CXCL6 secretion in colon cancer cells, which consequently exhibits a high invasive 
and metastatic property [221]. CXCL12 secreted by CAFs may also induce EMT as shown in 
oral squamous cell carcinoma [222] and breast cancer studies [223]. 
Interestingly, Gaggioli et al. showed that CAFs might act as guides at the primary site to 
facilitate the collective cancer invasion process, where they pave the way via generating 
ECM tracks and enhancing the stiffness [224]. The notion of collective migration was 
supported through many observations, which have revealed that cancer cells could stay as a 
group together maintaining their E-cadherin expression and do not acquire EMT [225-227]. 
Using a zebra fish model, CAFs isolated from prostate and colorectal cancer showed to 
induce cancer cell metastasis at the early stage of primary cancer growth. In the circulation, 
most of metastatic cancer cells showed to travel in tight association with CAFs [228]. 
Recently, an elegant colon cancer study showed that, CAFs induce cancer cell invasion by 
pulling and stretching the plasma membrane. Applying such contractile forces resulted in gap 
formation through the basement membrane allowing the cancer cells to move and invade 
easily. Interestingly, the authors observed that MMPs were not involved, and thus concluded 
that the effect was independent of basement membrane degradation [229]. Another 
interesting study showed that Tenascin C and VEGFA secreted by FSP1+ve fibroblasts at the 
metastatic niche, enhanced cancer cell metastasis. Depletion of FSP1+ve fibroblasts reduced 
the metastatic colonization significantly, while it did not affect primary tumor growth [230]. 
Cancer associated fibroblasts may induce invasion and metastasis via stimulating the 
angiogenic switch in the TME. In a gastric cancer mouse model, stromal fibroblasts enhance 
angiogenesis via VEGFA secretion upon activation by cancer cells [231]. Using prostate 
cancer xenograft model, CAFs expressing connective tissue growth factor (CTGF) 
significantly increased the micro-vessel density and tumor growth activity [232]. 
In recent years, the roles of exosomes in cancer biology have emerged massively, where 
several observations have highlighted the impact of those extra cellular vesicles on cancer 
invasion and metastasis [233, 234]. One of the studies demonstrated the promoting effect of 
CAFs derived-exosomes on lung cancer cell invasion and metastasis, via stimulating PCP 
(Wnt-Planar cell polarity) autocrine signaling in cancer cells [235]. An esophageal cancer 
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study showed that, fibroblasts upon activation by tumor cells in vitro, secrete exosomes 
holding miRNA-45, which in turn induces cancer cell growth and migration. The same 
miRNA was detected in the serum of 39 esophageal squamous cell carcinoma patients [236].    
In order to metastasize cancer cells need to colonize into a distant tissue. Therefore they 
prime the target tissue in advance, and recruit stromal cells at the metastatic site [43, 237]. 
Malanchi et al. showed that infiltrating mammary cancer stem cells, could prime and recruit 
lung fibroblasts to overexpress periostin, which stimulate Wnt signaling in the cancer cells 
and promote their colonization efficiency [238]. Similar observations were obtained in PDAC 
metastasized to liver, whereas hepatic stellate (fibroblasts) cells activation and periostin 
induction was triggered through granulin secreted by tumor associated macrophages [239]. 
It is evident that CAFs are important for tumor growth, invasion and metastasis, however 
several observations suggested additional impact of CAFs as immune modulation and drug 
resistance intermediation (Figure 6).  
1.7.4 CAFs as immune modulators  
Cancer associated fibroblasts persistently receive-respond to the stimulations, and their 
secretome dynamically evolves during all tumorigenesis stages. Therefore, they potentially 
affect the other cells in the TME, in particular the immune cells. Most of the available 
evidences state CAFs as immunosuppressive agents, however the majority of observations, 
are based on in vitro studies. Whereas, demonstrating in vivo studies could be quite difficult, 
due to the complexity and plasticity in the TME, which keeps all different cellular and non-
cellular compartments enthusiastically, interacted.   
It has been detected that CXCL12 and CCL2 producing CAFs could recruit macrophage into 
the TME, and support their differentiation into TAM-2 [240]. IL6 produced by CAFs could 
restrict the maturation of dendritic cells and redirect monocyte toward macrophage 
differentiation[241, 242]. The MDSCs could also be recruited by fibroblast-secreting 
chemokines; MDSCs had the potency to induce angiogenesis, participate in recruitment of T-
regs, and inhibit NK and T cell activity in the TME [243]. Kraman et al. showed that upon 
depletion of FAP in fibroblasts (using a transgenic FAP-ve mouse model), only 2% of 
injecting tumor cells (Lewis lung carcinomas cell) could develop in a tumor, and the anti-
tumorigenic effect was mediated through interferon-γ and TNFα beside the recruitment of 
CD8+ve T cells into the TME [244].  
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Similarly, a murine breast cancer study showed that CAFs, via immune suppression of TME, 
promote tumor development and metastasis. They found that the depletion of CAFs, via 
targeting FAP+ve cells, resulted in recruitment of cytotoxic T cells, dendritic cells and 
decreased the recruitment of pro-tumorigenic TAM as well as reduction in angiogenic switch 
[245].  
 
Figure 6. The role CAFs in tumorigenesis. CAFs promote tumor cell proliferation and invasion, induce 
stemness and drug resistance, enhance angiogenesis and ECM remodeling, facilitate metastatic colonization as 
well as, they increase inflammation and cause immunosuppression. Adapted and modified from [237], according 
to the agreement with Springer and Copyright Clearance Center. 
1.7.5 CAFs and drug resistance 
Beyond the availability of different treatment strategies and despite the progress made in 
targeting cancer, still the majority of patients get relapse or recurrence. Usually, few cancer 
cells or colonies sustain their survival machinery program upon the exposure to the treatment, 
and gradually become reprogramed. Such cells can re-grow massively while not responding 
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to further drug treatment; eventually, they acquire drug resistance, which is highly driven by 
the TME [246, 247]. Cancer associated fibroblasts, within the TME, emerged as one of the 
main players directing cancer cell survival and resistance to therapies. In a breast cancer 
study, it was proposed that elevated stromal-gene signature correlate with resistance to 
chemotherapy (cyclophosphamide, epirubicin and 5-fluorouracil) [248]. Cancer associated 
fibroblasts induce anti-cancer drug resistance through modulating the pathways involved in 
ECM-cancer cell interaction, cytokines and chemokines signaling, or even via CAF-cancer 
cell direct contact [249]. The recent BRAF-mutant melanoma study indicated the important 
role of CAFs in enhancing the resistance to BRAF inhibitors. A fibronectin-rich and stiffer 
TME was generated through the action of melanoma- associated fibroblasts; consequently, 
tumor cell survival was maintained by fibronectin-activating β1-integrin-FAK-ERK signaling 
in melanoma cells [250]. Another study showed that CAFs secrets MMPs that enhance anti-
EGFR drug resistance in head and neck cancer cells [251]. Moreover, CAFs secretome 
conferred pro-survival signaling cascades in tumor cells upon the exposure to drug treatment. 
Wnt-signaling showed to be triggered in cancer cells via the secretion of WNT16B and 
SFRP2 ligand by the CAFs; Wnt activation attenuated the effect of cytotoxic drug on prostate 
cancer cells, in vitro and in vivo [252, 253]. IL6, IL1β and IL8 showed to be overexpressed by 
prostate fibroblasts upon the exposure to chemotherapy, and such induction increased the rate 
of tumor cell survival, growth and invasion [254]. In luminal breast cancer model, the IL6 
secreting CAFs augmented cancer cell survival and the resistance to tamoxifen treatment 
[255]. The effect of CAFs, inducing resistance to treatment, is not restricted to cytostatic drug 
therapy, but also to immune therapy. In a PDAC model, CXCL12 expressing CAFs could 
reduce the effect of anti-CTLA-4 and PD-L1 antagonists on tumor cells. Targeting the 
CXCL12-CXCR4 signaling pathway recruits cytotoxic T cell rapidly resulting is a potent anti-
tumorigenic environment, thus diminishing the PDAC cell growth [256].   
Targeting CAFs in the TME is highly recommended, and anti-stromal drugs may offer new 
strategies to overcome drug resistance drawback. However, more systematic and 
comprehensive studies are required to identify the specific targetable-signaling cascades in 
CAFs within a specific TME.  
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2 AIMS OF THE THESIS 
The present thesis is aiming to investigate the roles of normal versus cancer-associated 
fibroblasts in the tumor microenvironment. 
Specifically, the thesis addresses the following questions and tasks:  
1. The elucidation of the role of normal fibroblasts in the so-called “neighbor 
suppression phenomenon”.  
2. The identification of the main signaling pathways linked to the suppressor capacity of 
fibroblasts upon activation by tumor cells. 
3. To investigation of the possibility of switching the phenotypic behavior of fibroblasts 
from cancer suppressing to cancer promoting and the other way around. 
4. To development of a comprehensive live cell-imaging tool, and validating it via 
exploring the effects of CAFs on the growth and chemotherapeutic response of cancer 
cells. 
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3 RESULTS AND DISCUSSION 
The thesis presents four projects that can be divided into three categories: 
Ø The suppression effect of normal fibroblasts on tumor growth and development 
(Paper I and II, Figure 7 and 8). 
Ø The link between tumor suppression and tumor promoting phenotypes in fibroblasts  
(Paper III, Figure 9). 
Ø The promoting effect of CAFs on tumor cell growth and drug resistance (Paper IV). 
3.1 FIBROBLASTS INDUCE TUMOR GROWTH INHIBITION: THE 
INVOLVEMENT OF VARIOUS GENES, PROTEINS AND SIGNALING 
PATHWAYS 
3.1.1 Neighbor suppression: the two step phenomenon  
Several studies have documented the so-called neighbor suppression phenomenon. However, 
only few of them have demonstrated the effect-driving factors; if so they exhibited 
contradictory findings [145, 149, 151, 257]. Therefore, we have studied and identified the 
main players that direct the tumor-inhibition process by fibroblasts.  
Previously, two sub-clones of the immortalized human fore skin fibroblasts BjhTERT were 
identified based on their differential tumor-inhibition efficiency in vitro [155]. The most 
suppressive one, also called whirly, was selected and used in our study. We have challenged 
the concept of neighbor suppression to prove the contact dependent assumption. To this end, 
we collected the secretome (the conditioned media, CM) from tumor-activated fibroblast 
cultures (a fibroblast-tumor cell co-culture), and from cultures of non-activated fibroblasts 
(fibroblasts alone), respectively. Incubating PC3 prostate cancer cells with both types of 
secretomes did not alter their proliferation efficiency (as measured for 5 days using a 384-
well plate-high throughput inhibition assay [154]). This suggested that the tumor inhibition 
process couldn’t be triggered by soluble factors secreted by fibroblasts. Next, we examined 
the contact dependent effect upon elimination of secreted, soluble factors. For this, the 
fibroblasts monolayer was fixed with 4% formaldehyde, keeping the ECM, the adhesive, and 
the trans-membrane proteins tight and intact, and PC3 cells were added. An incomplete 
inhibition of PC3 cell proliferation was observed. A complete inhibition was referred to the 
condition when PC3 cells were co-cultured with a live and dynamic fibroblast monolayer. 
The status of incomplete inhibition did not change when the co-culture was incubated with 
the CM from non-activated fibroblasts. Interestingly, the CM from the tumor-activated 
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fibroblasts significantly boosted the suppressive effect of the formaldehyde fixed fibroblasts 
monolayer; the inhibition was retained to a level close to a complete inhibition score. This in 
turn suggests that the activation of fibroblasts by tumor cells is crucial for stimulating the 
secretion of anti-tumor soluble factors, which can only be effective when there is a direct 
contact between fibroblasts and tumor cells. A number of studies have indicated the 
important role of fibroblasts in restricting tumor growth and development. Upon reducing 
the content of stroma, via deleting the Sonic hedgehog gene in a mouse PDAC, a more 
aggressive tumor was generated, which was characterized by an undifferentiated histology 
and high proliferation efficiency [258]. Using a similar PDAC mouse model, another study 
showed that upon targeting and depleting αSMA-positive fibroblasts in the mouse, a highly 
invasive tumor developed. Such a tumor was characterized by enhanced EMT, hypoxia, a 
stem cell-like phenotype, and also by reduced animal survival [259]. Interestingly, in 
attempting to reconstruct a human mammary epithelial tissue in mice, Weinberg and 
colleagues, found that normal activating fibroblasts were responsible for the configuration 
of normal epithelial phenotype. Furthermore, they found that patient epithelial cells injected 
in humanized cancer associated microenvironment yielded a cancer similar to human ductal 
carcinoma. Such a phenotype was normalized when the normal fibroblasts were co-injected 
with patient cells [260].  
Furthermore, to investigate whether the neighbor suppression effect is restricted to cell 
proliferation or can be extended further beyond tumor cell motility, we have also monitored 
the motility of PC3 cells using extended field time-lapse imaging. Similarly, CM from tumor-
activated fibroblasts, but not from the non-activated ones, significantly enhanced the 
suppression of PC3 cell motility upon contact with the formaldehyde fixed fibroblasts 
monolayer. 
Eventually, our finding demonstrated that the neighbor suppression effect of fibroblasts 
against tumor cell proliferation and motility has a multifactorial effect assembled into two 
steps: the first representing the ECM, the adhesive and the trans-membrane proteins in 
fibroblasts, which via direct contacts with tumor cells initiate the process of inhibition. Such 
fibroblasts-tumor cell interactions enhance the secretory machinery (most likely in 
fibroblasts), which represent the second group of factors that further induce the suppression 
process. 
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3.1.2 Tumor suppressive fibroblasts exhibit different genes and proteins 
signatures  
Since both types of CM exhibited diverse functional impacts on tumor cell proliferation and 
motility, we wanted to analyze the nature of those differences.  In order to do so, we used an 
Antibody Array-Kit for checking the expression of soluble proteins in both types of CM. Out 
of 507 analyzed proteins, nine of them displayed differential expression pattern namely: 
GDF15, MMP3, CXCL2, EMAP-II, Galectin-3, uPA, DKK1, Nidogen1, and EDA-A2. GDF-
15 (growth differentiation factor 15) was the only one, which was missing in the non-
suppressive CM but was highly overexpressed in CM from the suppressive phenotype, which 
might reflect the suppressive property of tumor activated CM. It has been shown that GDF15 
can inhibit MCF7 proliferation via inducing the activation of p53 and p21 [261].  In a 
transgenic mice model, the ubiquitous expression of GDF15 resulted in an intestinal adenoma 
resistant phenotype [262]. However, other studies have presented GDF15 as a soluble factor 
that exhibit opposite effects; showing tumor promoting effects as well [263]. Recently, 
GDF15 was recommended to be included in routine prostate cancer screening strategies as a 
prognostic factor for aggressiveness [264]. Nevertheless, our analysis was limited to ≈500 
proteins, still many secreted factors have not been identified, that could be responsible for the 
inhibition, including but not limited to, exosomes and microRNAs; such factors were 
investigated in separate study (not included in the thesis).  
To identify the main genes involved in the process of cancer cell inhibition, the complete 
transcriptome of fibroblasts before and after activation by tumor cells was verified and 
compared. Using Affymetrix microarray-gene chips, more than 1000 differentially expressed 
genes (617 as overexpressed and 402 as downregulated genes) were identified in fibroblast 
upon activation by tumor cells. Among the proinflammatory, adhesion and ECM genes, 
eleven differentially expressed candidates have been selected. Eight of them were 
upregulated including CXCL1, CXCL2, COL15A, ICAM1, IL-1b, IL-6, IL-8, and MYO10, and 
three were downregulated ADAMTS1, SPP1and TNFRSF11B. This group of candidates was 
further verified via q-PCR analysis. The overexpression of proinflammatory genes might not 
represent the inhibition status of fibroblasts, due to the fact that most of these cytokines and 
chemokines were shown to be involved in induction of tumor growth, progression, 
invasiveness, and resistance to treatment [265, 266]. However, It has been shown that 
proinflammatory cytokines, via inhibiting IGF-I, could induce growth arrest in MCF7 breast 
cancer cells [267]. Therefore, one could argue that the effect of proinflammatory genes is 
context dependent; in our experimental setup there is a direct effect on tumor cells, whereas  
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Figure 7. The inhibition of cancer cell growth is contact and soluble factor dependent. 
in other models (mice and patients) the complexity of the TME, as different players interact 
with each other, drive the effect in different way. On the other hand, the other three-
downregulated genes could be important players for controlling the inhibition of tumor cell 
proliferation and motility. Several observations indicated that CAFs enhance tumor growth 
and invasion via inducing the secretion of any of ADAMTS1, SPP1and TNFRSF11B [268-
270]. The differentially expressed genes and proteins selected in our study might act 
collectively but not individually; the signaling cascades, triggered via the activation or 
suppression of selected candidates interfere with each other directing various signaling 
outcomes. Therefore, more comprehensive studies are required to identify the main signaling 
pathways involved in controlling tumor inhibition process by fibroblasts.  
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3.1.3 Activated- and tumor suppressive- fibroblasts exhibit differential 
signaling pathways signature  
The notion of drawing scientific conclusions based on a differentially expressed gene or 
protein (cytokine, chemokine, ECM etc.), that transduces signals in one directional flow, has 
been argued against. Simply put, the signal transduction process represents a network of 
signaling pathways that operate and interact with each other to drive particular physiological 
processes (cell division, migration, apoptosis etc.). Applying similar concepts and using 
system biology approaches [271, 272], we have investigated all the possible links and 
pathways correlated to fibroblasts suppression effect and upon activation by tumor cells. 
Four pairs of fibroblasts were used in this study; each pair represented two fibroblasts with 
high and low tumor suppressive functions, respectively. One of the pairs was whirly and 
crossy, a sub-clone of BjhTERT cell line (as mentioned previously, see page 29 and [155]), 
and the other three were primary cells isolated from patients and/or donors (normal and 
cancerous area from prostate cancer patients, adult normal skin, pediatric skin and hernial 
samples). All fibroblasts were co-cultured with PC3 prostate cancer cells and their inhibition 
score was determined after five days (using 384-well inhibition assay). The inhibition score 
revealed that whirly, normal prostate, and skin fibroblasts were more suppressive, while 
crossy, hernia, and prostate cancer fibroblasts were less or non-suppressive, respectively. At 
the same time, Affymetrix microarray analysis was performed on 16 samples of fibroblasts 
(all eight fibroblasts before and after activation by PC3 cells). Three sets of differentially 
expressed genes (DEG) were selected as comparing the transcriptomic signature between A) 
fibroblasts before and after tumor cell activation, B) suppressive versus non-suppressive 
fibroblasts before tumor cell activation, and C) suppressive versus non-suppressive 
fibroblasts after tumor cell activation. All genes that showed low expression level, as variance 
<0.1 and mean <4, were neglected.  
To investigate the functional relevance of each DEG set, we have performed a network 
enrichment analysis (NEA); identifying the signaling pathways, which would be affected by a 
particular DEG set. The full set of DEG/group was relatively large, however, we chose and 
compared the significance of three sub-sets (top- 30, 100, and 300 genes that were 
differentially expressed) on the known signaling pathways (selected from different sources, 
including Reactome, KEGG, WikiPathways, BioCarta, and others). Each of these pathways 
composed of a set of genes/proteins, which called functional gene set (FGS); the links 
between DEG to FGS were determined and the observations were considered significant 
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when the false discovery rate (FDR) were bellow 0.1 with a minimum of 5 links. The 
statistical power of the observations was proportional with the size of the DEG sub-set; the 
300 genes list was the most significant one and therefore was the only reported sub-set. In 
group A (DEG in fibroblasts after PC3 activation as compared to non-activated fibroblasts), 
76 pathways were significantly enriched, however the number of links per pathway was 
changing between 20 to 998 links. The top five pathways that exhibited the largest number of 
links were: focal adhesion (998 links), TNFα-NFκβ-signaling pathway (932 links), regulation 
of actin cytoskeleton (834 links), RhoA-signaling pathway (824 links), and chemokine 
signaling pathway (770 links). Such results support previous observations, where fibroblasts 
upon interaction with tumor cells, showed to change their contractile and stiffness status [273, 
274]. In group B (DEG in suppressive fibroblasts as compared to non-suppressive fibroblasts 
before PC3 activation), 56 pathways were significantly enriched. The first 5 pathways 
indicated with highest number of links were: RhoA-signaling pathway (578 links), focal 
adhesion (512 links), chemokine signaling pathway (476 links), Wnt-signaling pathway (450 
links) and regulation of actin cytoskeleton (442 links). Interestingly, in group C (DEG in 
suppressive fibroblasts as compared to non-suppressive fibroblasts after PC3 activation), only 
one pathway was enriched (the TNFα-NFκβ-signaling pathway) but with the highest number 
of links (1572) as compared to all other groups. Changes in this pathway and its signaling 
cascades have been shown to be involved in both tumor growth as well as in regression [275].  
It is important to highlight that our DEG sets were obtained via considering all 8 fibroblasts 
similar, however they were originating from different sites and tissues as well as being 
primary or immortalized cells. Therefore, we have selected two pairs (first pair: whirly and 
crossy that originate from skin and they are immortalized fibroblasts, and second pair: normal 
prostate and cancerous prostate fibroblasts, which represent primary ex vivo cells), to analyze 
whether their pathway score is correlated to each other or not. We observed that both pairs 
were highly associated on the pathway level (Spearman rank R = 0.686, p < 10−18), despite 
that they showed differences on the DEG list (only 59 DEGs were identical).  
Apart from the signaling pathways, and via using NEA, we have also identified a number of 
transcription factors and other regulatory genes, which were enriched in each set of DEGs. In 
this way we could identify individual genes, which were not known to be members of any 
particular pathway; for example, we found that RelA (P65), a NFκβ-signaling mediator, 
regulate genes involved in Rho-signaling such as NET1 (neuroepithelial cell transforming 
factor), NFKBIA (NF-kB inhibitor), IL1B, the RELT (TNF receptor), and BHLHE40. 
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Figure 8. The potential signaling pathways altered in fibroblasts, upon activation by tumor cells and in 
correspondence to the tumor suppressive functions. 
 
3.2 FIBROBLAST ACTION: FROM ANTI-TUMORIGENIC INTO PRO-
TUMORIGENIC PHENOTYPE 
3.2.1 Targeting RhoA gene in fibroblasts enhances tumor cell proliferation 
and motility 
RhoA-signaling plays an important role in tumor growth and migration [276, 277]. Both our 
recent and previous data indicated the role of RhoA-signaling in the TME. As we showed via 
in NEA (mentioned in the previous section, page 33), RhoA-signaling was ranked the first 
among all the signaling pathways, which significantly correlated to fibroblasts suppression 
effect against tumor cell growth and proliferation. Additionally, our group have previously 
identified 12 novel markers for CAFs, where four of them were related to Rho GTPase 
signaling and the fifth one was related to RhoA-signaling. Therefore, to investigate the direct 
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effect of RhoA on the functions of fibroblasts as anti- or pro-tumorigenic cells in the TME, 
we have targeted and deleted the RhoA gene in the fibroblasts.  
Using CRISPR/cas-lenti virus knocking-out system, we could eliminate the RhoA gene in 
BjhTERT fibroblasts. The expression level of RhoA on the gene and protein level was 
confirmed. The rate of tumor cell (PC3 cells) proliferation was determined in the presence of 
RhoA-knock out BjhTERT cells and their corresponding control cells (infected with empty 
vector-lenti viral particle). Tumor cell proliferation efficiency was increased significantly in 
the presence of RhoA deficient fibroblasts as compared to RhoA expressing fibroblasts.  
We also have examined the effect of RhoA expression on the function of fibroblasts as 
stimulator or suppressor of tumor cell motility in vitro. The motility of PC3 cells was 
increased significantly (they also exhibited big sized colonies) upon co-culture with RhoA 
deficient BjhTERT as compared to the co-culture with RhoA expressing BjhTERT cells 
(control cells). Our results indicate that the suppressive effect of fibroblasts against tumor cell 
proliferation and motility can be modulated into a stimulatory one, with RhoA as the 
suggested main driver of this modulation.  
3.2.2 RhoA knock-out fibroblasts induce tumor formation in mice and tumor 
cells compactness in 3D-collagen matrix 
To investigate the effect of RhoA deficient fibroblasts on tumor initiation and development in 
vivo, we have co-injected PC3 and BjhTERT (RhoA knock-out and wt control cells) 
fibroblasts in SCID and SCID-beige mice. Our experimental setup included the injection of a 
non-tumorigenic dose of PC3 cells; 20.000 PC3 cells when injected alone were unable to 
initiate tumor growth in vivo. Upon co-injection of the same number of PC3 cells with 1 x 106 
BjhTERT control cells, only two out of fifteen mice developed small tumors. Whereas all 
mice co-injected with the PC3-RhoA deficient fibroblasts got tumors; they started to grow 
after 6 – 7 weeks, followed by an enormous growth where the size of tumor mass became 1 
cm3 in two weeks.  
Our in vivo and in vitro observations highlight the importance of RhoA expression in 
fibroblasts to maintain their anti-tumorigenic phenotype. The inactivation of RhoA gene 
expression in fibroblasts or TME showed a pro-tumorigenic action. On the contrary, 
activation of RhoA-signaling in cancer cells appeared to be vital for their growth and 
invasiveness. It has been shown that activation of RhoA in human mammary epithelial cells 
enhances their pre-neoplastic transformation and directed their immortalization [278]. 
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Another study showed that RhoA was mutated in more than 25% of diffuse-type gastric 
carcinoma; where the mutations showed a gain-of-function behavior [279].  
Furthermore, we have analyzed the growth of tumor cells in 3D collagen matrix. Here PC3 
cells were co-cultured with RhoA deficient and control BjhTERT cells, in collagen spheres 
for seven days, respectively. We found a significant induction of PC3 cells clustering and 
compactness in RhoA deficient fibroblasts co-cultures as compared to control fibroblasts co-
cultures. Such compactness of tumor cells increases the efficiency of cell-cell contact, and 
may boosts cancer cell survival, as well as it may induce the stem cell like properties in PC3 
cells. This finding support our in vivo observations, where the onset of the tumor was delayed 
to week six or seven, but precipitously increased within two weeks later. We have 
hypothesized that, six weeks were required to induce the compactness and stemness in cancer 
cells, and when such level of compactness was achieved the cancer stem cells boosted the 
growth massively. It has been shown that cancer stem cell-phenotype could be enhanced by 
cell-cell contact and via soluble factor secreted by the TME [280]. Therefore, we wanted to 
investigate what kind of secretory function the BjhTERT- RhoA deficient fibroblasts display 
when they are in co-culture with tumor cells. We therefore performed an Affymetrix 
microarray analysis on both BjhTERT (control and RhoA deficient) cells, with and with out 
PC3 co-culture. Interestingly we found that BjhTERT-RhoA deficient fibroblasts, in response 
to tumor cell stimulations, overexpress high amount of proinflammatory genes including IL8, 
IL-1α, IL-6, IL-1β, CCL2, and TNFAIP2, which were further validated by qPCR analysis. 
This finding further supports our stemness induction hypothesis. Recently, it was shown that 
mesenchymal-stromal cell in the TME induced stemness of osteosarcoma cells via secreting 
IL8, IL6, CXCL1, CXCL5, CCL5 and activating NF-κβ signaling [281]. In addition, another 
study showed that inflammation induces the expression of stemness-related markers in 
hepatocellular carcinoma [282].  
3.2.3 RhoA knock-out fibroblasts exhibit differential cytoskeleton structure 
and stiffness properties 
Upon the elimination of RhoA expression in BjhTERT, the fibroblasts displayed various 
modifications in the structure of cytoskeleton, represented mainly by less actin stress fiber 
and large focal adhesion. They also showed a very low αSMA-expression level, as compared 
to the control cells. Suggesting that such tumor stimulatory fibroblasts does not follow the 
classical CAFs characteristics; our results further supported other findings, which indicated 
that αSMA is not the universal marker for CAFs [283]. 
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To evaluate whether the cytoskeleton modifications were related to the alterations in the 
mechanical properties of the fibroblasts, both the stiffness and contractile force were 
measured via atomic force and traction force microscopy, respectively. RhoA deficient 
fibroblasts showed a significant decrease in contractile force, but a more homogenous and 
distributed elastic modulus, as compared to control fibroblasts. The elastic modulus 
represents the cell stiffness, which was significantly higher in RhoA deficient cells.  Such 
shift in fibroblasts phenotype, due to the knocking-out of RhoA gene, clearly highlights their 
tumor stimulatory phenotype. It has been documented that alterations in the mechanical 
properties of the TME induce tumor initiation and development [284]. Recently, it was 
shown that Biglycan induced fibroblasts stiffness, which promotes melanoma cell growth and 
invasiveness [285].  
 
Figure 9. Tumor suppressive fibroblasts turn into tumor promoting cells. Targeting the RhoA gene in 
fibroblasts boosts tumor initiation in vivo, induces tumor colony compactness in 3D-collagen matrix, and reduces 
tumor suppressive function in vitro. 
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3.3 CANCER ASSOCIATED FIBROBLASTS MODULATE TUMOR CELL 
GROWTH AND THEIR RESPONSE TO CHEMOTHERAPY: METHOD 
DEVELOPMENT AND APPLICATION 
3.3.1 Developing a quantitative live cell-imaging system to study           
tumor-fibroblasts interactions in vitro 
It is evident that fibroblasts along with the other TME compartments play an essential role 
driving cancer growth, invasion and response to drug treatment. Therefore, we cannot neglect 
the effect of the TME while studying tumor cell growth and the response to drug treatment in 
vitro. Accordingly, we have developed a tool to study the effect of cancer cell-fibroblast 
(TME) interactions on tumor cell activity, growth, and the response to various types of 
treatment. Basically, the proliferation, motility, and phenotypic plasticity of tumor cells and 
fibroblasts could be observed and quantified using live cell imaging system combined with 
quantitative MATLAB-based analysis. In this study, the tumor cells-fibroblasts co-cultures 
were followed continuously for three days; thus, tumor cell proliferation and motility could 
be measured by a kinetic rather than an endpoint method. 
The need of developing a new tool was essential due to the fact that majority of available 
methods and in vitro systems are limited to one type of cell and cannot be applied to co-
culture conditions. Furthermore, the existing tools are mostly determined by measuring a 
single parameter, which could be one of the vital physiological processes, such as cell 
proliferation, cell death, metabolic activity or migration. Moreover, mentioned approaches 
are restricted to a specific time point conditions (endpoint assays); therefore, the outcome 
might not be thoroughly informative. Such as, the high probability of getting false positive or 
negative results, using cell proliferation assay (e.g. BrdU / EdU incorporation assay [286]), 
when investigating the response of cancer cell to a particular treatment. False results can be 
obtained for example if few populations of cancer cells have very low proliferation capacity 
accompanied by active migratory and invasive properties [287, 288]. Our method provides 
the possibility to overcome such challenges by following tumor growth real time at single cell 
level, via indexing each separately 
3.3.2 Induction of ovarian cancer cell growth and the resistance to 
chemotherapeutic drug by CAFs  
To validate our method, and as a proof of principle, we have studied the effect of CAFs on 
epithelial ovarian cancer cell growth and their response to cisplatin (CDDP) treatment. Beside 
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the high mortality rate, the choice of ovarian cancer model for this study was based on the 
fact that the majority of patients relapses and acquires resistance to drug treatment [289]. 
Therefore, we wanted to understand the nature of such resistance with particular focus on the 
putative involvement of CAFs.  
 In this work, the proliferation and motility of ovarian cancer cell line (OC) and patient-
derived ovarian cells (PDOC) were monitored in the presence or absence of CAFs. Our 
results revealed that CAFs induced cancer cell proliferation and motility. However, the effect 
of CAFs on PDOCs proliferation was not clear, because most of PDOCs were slow growing 
cells by nature (with a doubling time > 72 hours). On the other hand, the motility of PDOCs 
and OCs cells was dramatically enhanced in the presence of CAFs. Without measuring the 
motility, we would only interpret our observations based on the proliferation rate, which 
might then direct us into different conclusions. Therefore, it’s highly important to consider 
both cell proliferation and motility while investigating the growth of tumor cells in any 
experimental condition. Additionally, our results were in line with the majority of previous 
observations, where they showed that CAFs induce cancer cell growth and invasion [290, 
291].  
Next, we tested the effect of CDDP treatment on OCs and PDOCs before and after the co-
culturing with CAFs. The cancer cells heterogeneously responded to the drug, as some of 
them were more sensitive than the other to CDDP treatment. Interestingly, CAFs induced the 
survival of cancer cells under CDDP treatment; both motility and the proliferation of OCs 
were induced by CAFs upon treatment. The same was true for PDOCs, where the survival 
index showed induced motility efficacy. As mentioned earlier, CAFs were shown to play an 
important role in the induction of cancer cell growth and resistance to chemotherapy. For 
example, in a melanoma study, fibroblasts induced cancer cell resistance to vemurafenib 
[292]. Similarly, in a breast cancer study, exosomes produced by fibroblasts directed cancer 
cell resistance to radiation and chemotherapy [293]. Here, we show that CAFs drive the 
resistance of ovarian cancer cells to CDDP treatment. This in turn, suggests that a new 
treatment strategy is required, where the combinational therapy targeting CAFs and tumor 
cells simultaneously is necessary. 
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4 CONCLUSIONS 
The ambition of the present doctoral thesis was to investigate the role of fibroblasts in the 
process of tumorigenesis. Using in silico, in vitro, ex vivo, and in vivo experimental 
approaches, we could clearly demonstrate that fibroblasts have a “reciprocal action in the 
TME”.  Our observations indicated that fibroblasts could either suppress or promote tumor 
growth and development.   
 Specifically, I present the following conclusions: 
I. The suppression of tumor cell proliferation and motility by fibroblasts requires two 
signals: the first is vital and originates from the structural configuration of the 
transmembrane proteins of the fibroblasts, which are in tight contact with the ECM. 
The second signal is dependent on the soluble factors secreted upon fibroblasts-tumor 
cell interactions. Specifically, the first signal is essential for initiating the process of 
suppression, while the latter for boosting it. 
II. Fibroblasts-tumor cell interactions revealed the alteration of different signaling 
pathways in fibroblasts, suggesting potential mechanisms for fibroblasts suppression 
effect against the growth of tumor cells. For example, RhoA, cytoskeleton 
reorganization, chemokine, and TNFα-NFκβ-signaling pathways were found to be 
involved in directing fibroblasts activation and suppression phenotypes.     
III. RhoA drives the modulation of tumor suppressor fibroblasts into a tumor stimulatory 
ones. Eliminating the RhoA gene in fibroblasts resulted in: A) Inhibition of the 
fibroblast-mediated suppression of tumor cell proliferation and motility in vitro, B) 
Enhancement of fibroblasts-mediating tumor cell compactness in 3D-collagen 
spheroids, and C) Fibroblasts-mediated induction of tumor growth and development 
in vivo. Ablating of RhoA in fibroblast was resulted in increased cellular stiffness, 
disorganized cytoskeleton, and decreased cellular contractility; accompanied by 
induction of proinflammatory signature, only after contact with tumor cells. 
IV. Our quantitative live cell-imaging tool highlighted the significance of monitoring 
tumor-fibroblasts interactions kinetically; implicating tumor cell proliferation and 
motility as essential parameters. 
V. Cancer associated fibroblasts enhanced ovarian cancer cell survival and their 
resistance to CDDP treatment. 
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5 ONGOING AND FUTURE PERSPECTIVES 
In Paper I, we identified GDF15 (a member of TGFβ superfamily [294]) as one of the 
primary candidates, which may direct the suppressive function of fibroblasts against 
proliferation and motility of tumor cells. Therefore, we targeted GDF15 in fibroblasts via 
CRISPR/cas and shRNA lentiviral silencing system, respectively. Next, we realized that 
tumor cells could produce GDF15 as well, thus we have targeted the gene in tumor cells, in 
the same way. The aim is to investigate the effect of GDF15 on tumor cell-fibroblasts 
crosstalk and the suppressive action of fibroblasts.  
We have also checked the polymorphism of GDF15 gene in normal fibroblasts and CAFs. 
Aiming for the identification of specific isoforms that correlates to anti- and pro-tumorigenic 
properties of fibroblasts, as well as, to survival rates in patients with different types of 
epithelial tumors.    
Furthermore, in Paper I, ECM produced by fibroblasts shown to plays a significant role in 
the suppression of tumor cell proliferation. Therefore, we aimed to compare the ECM 
signature between a range of normal fibroblasts and CAFs using RT-PCR ECM-kits. A set of 
candidates have been selected, and we now want to define the possible signaling pathways 
linked to the DEGs set, using the same approach that was implemented in (Paper II). Our 
main goal is to target three to four candidates from the same pathway at once (targeting the 
pathway rather than a single gene). The system has been optimized using a lentiviral-
silencing approach in a 384-well plate. 
In Paper IV, we developed a live cell-imaging tool to study the effect of CAFs on ovarian 
cancer growth and response to CDDP treatment. Now, the goal is to develop this tool further, 
by shifting it from 2D semi-throughput into a 3D high-throughput system. Additionally, 
identifying the mechanism(s) through which the CAFs induce ovarian cancer cell survival 
and resistance to platinum treatment, is one of our most important future goals. 
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